NZCR is at the forefront of early phase clinical research. Our focus on quality and innovation has resulted in many exciting medical breakthroughs. These news articles highlight current research projects and innovations at NZCR.
Home / About Us / About NZCR / News
NZCR Clinical Trial - Universe Study showing exciting results
Hope offered by new ALS research findings
NZCR and Verve Therapeutics - Gene Editing Study includes first patient in Auckland New Zealand.
Our research partner Alvotech has announced positive results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara® conducted at NZCR research facilities.
NZCR Lead Research Physician Dr Alexandra Cole, CEO Dr Christian Schwabe and Business Development Manager, Marcus Burrows are pleased to be representing NZCR at ARCS 2022 in Sydney this week.
New Zealand Clinical Research (NZCR) is putting put out a call for healthy males in Auckland and Christchurch to be part of two large trials researching potential new treatments for breast cancer.
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab
biosimilar, in healthy adult subjects
NZCR is reducing medical waste and helping the Pacific Islands at the same time
NZCR staff received a lovely surprise this week.
Alvotech receives EU approval for AVT02
NZCR- AKL has opened their new outpatient facility today.
NZCR Supports Covid -19 Vaccination for all New Zealanders.
New Zealand Clinical Research (NZCR) provides state of the art research facilities and the expertise to conduct complex early phase clinical research in healthy participant and patient populations.